JZYY(SH:600750)2024-10-25 10:25Financial Performance - The company's operating revenue for Q3 2024 was ¥799,352,122.10, a decrease of 8.64% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥145,587,454.62, representing a slight increase of 2.15% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥144,317,854.68, showing a decrease of 0.64% compared to the previous year[3]. - Total operating revenue for the first nine months of 2024 was CNY 2,971,879,125.96, a decrease of 8.2% compared to CNY 3,236,916,800.27 in the same period of 2023[23]. - Total operating costs for the same period were CNY 2,215,871,404.32, down 13.1% from CNY 2,549,157,745.08 year-over-year[23]. - Operating profit increased to CNY 806,852,228.86, compared to CNY 731,516,551.39 in the previous year, reflecting a growth of 10.3%[23]. - The total profit for Q3 2024 was CNY 807,563,569.73, an increase from CNY 738,065,247.24 in Q3 2023, representing a growth of approximately 9.1%[24]. - The net profit attributable to shareholders of the parent company reached CNY 634,340,897.79, up from CNY 592,326,126.97 in the same period last year, reflecting an increase of about 7.1%[24]. - Basic and diluted earnings per share for Q3 2024 were both CNY 1.01, compared to CNY 0.94 in Q3 2023, indicating a growth of approximately 7.4%[25]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥6,126,752,091.97, a decrease of 0.03% from the end of the previous year[4]. - Total assets amounted to CNY 6,126,752,091.97, slightly down from CNY 6,128,543,353.58 at the end of the previous quarter[21]. - Total liabilities increased to CNY 1,894,757,777.87, up from CNY 1,653,436,913.49, indicating a rise of 14.6%[21]. - The company's equity attributable to shareholders decreased to CNY 3,717,863,952.26 from CNY 3,831,520,111.84, a decline of 2.9%[21]. - The company's cash and cash equivalents as of September 30, 2024, amount to ¥907,975,361.03, down from ¥1,332,928,513.42 at the end of 2023[19]. - The total assets as of September 30, 2024, amount to ¥2,028,393,575.15, down from ¥2,397,129,852.82 at the end of 2023[19]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥442,960,892.68, down 22.79% compared to the previous year[3]. - Cash flow from operating activities for the first nine months of 2024 was CNY 442,960,892.68, down from CNY 573,736,148.12 in the same period of 2023, a decrease of about 22.8%[25]. - Cash inflow from operating activities totaled CNY 3,020,914,317.85, compared to CNY 3,410,995,656.64 in the previous year, showing a decline of approximately 11.4%[25]. - Cash outflow from operating activities was CNY 2,577,953,425.17, down from CNY 2,837,259,508.52 in the same period last year, a decrease of about 9.1%[25]. - The net cash flow from investing activities was -CNY 79,610,953.21, an improvement from -CNY 514,881,214.49 in the same period of 2023[27]. - The total cash and cash equivalents at the end of Q3 2024 were CNY 557,405,366.27, compared to CNY 184,567,762.31 at the end of Q3 2023, indicating a significant increase[27]. - The company reported a decrease in cash received from sales of goods and services, totaling CNY 2,892,277,770.85, down from CNY 3,301,957,866.25 in the previous year, a decline of approximately 12.4%[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 38,276[13]. - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group, holds 271,071,486 shares, accounting for 43.09% of total shares[13]. - The company has no significant changes in the top ten shareholders or their participation in margin financing and securities lending[15]. Industry Performance - The pharmaceutical industry segment generated revenue of ¥2,940,670,027.53, down 8.35% year-on-year[8]. - Revenue from prescription drugs decreased by 25.10%, while non-prescription drugs saw a revenue increase of 2.78%[8]. - The revenue from the South China region increased by 1.88%, while the North and East China regions saw declines of 11.76% and 10.18%, respectively[9]. Investments and Acquisitions - The company acquired 100% equity of Jiangxi Jiangzhong Changrun Pharmaceutical Co., Ltd. and Jiangxi Jiangzhong Bencao Health Technology Co., Ltd. in November 2023[4]. - The company has entrusted a total of ¥180,000,000 in wealth management products, with expected annualized returns of 3.68% and 3.05% for different products[16]. - The company has a long-term equity investment valued at ¥30,935,089.44, slightly down from ¥31,295,176.87 in the previous period[19]. - The company has a non-recoverable loan of ¥6,750,000 from Changrong Automobile, with legal actions ongoing to recover the amount[18]. Research and Development - Research and development expenses rose to CNY 77,862,125.99, an increase of 9.0% from CNY 70,843,909.82 in the same period last year[23]. Future Outlook - Future outlook includes potential market expansion and new product development initiatives aimed at enhancing revenue streams[22]. - The company has not indicated any new product launches or significant market expansion strategies in the current report[28].